PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Seasonal allergic rhinitis

Drugs in development · updated 30 October 2026

Seasonal allergic rhinitis: drugs in development

As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 9 drugs for seasonal allergic rhinitis. 8 are experimental, that is not yet approved in the United States.

11Active trials
8Experimental drugs
5Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
GR1802III2NCT07199257
StapokibartCM310, StapokibatrtIII2NCT07678931
LP-003III1NCT07291284
RupatadineRupatadinIII1NCT07711262
SHR-1819III1NCT07688772
AK139II1NCT07436234
TQH2722II1NCT07398859
ITI-9001I1NCT07726147

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
TezepelumabTezspireII1NCT06189742

Sorted by most advanced phase and number of active trials.

All 9 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006255 “Rhinitis, Allergic, Seasonal”.

ItalianoFrançaisDeutsch